Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Organogenesis (Nasdaq: ORGO) will report fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 26, 2026.
Management will host a conference call and live webcast at 5:00 p.m. ET on February 26 to discuss results and provide a corporate update; the webcast will be archived on the company website for about one year.
Positive
- None.
Negative
- None.
News Market Reaction – ORGO
In the Feb 20 session, ORGO gained 0.25%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Executive promotions | Neutral | -4.8% | Avista Healthcare Partners promoted investment team members tied to ORGO’s board. |
| Dec 23 | BLA initiation | Positive | +2.1% | Initiated rolling BLA submission to FDA for ReNu in knee osteoarthritis. |
| Dec 15 | FDA meeting update | Positive | +0.2% | Reported successful FDA Type-B meeting and plan to begin rolling BLA for ReNu. |
| Nov 06 | Q3 2025 earnings | Positive | -2.0% | Posted record Q3 revenue, higher earnings, and raised FY2025 guidance. |
| Nov 03 | CMS payment reform | Positive | -5.9% | Highlighted CMS payment reform seen as supportive for skin substitute products. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive fundamental or regulatory news has produced mixed reactions: several favorable FDA/CMS and earnings updates saw both modest gains and notable selloffs, indicating inconsistent alignment between news tone and price moves.
Over the last few months, ORGO has reported several significant milestones. On Nov 3, 2025, it highlighted CMS payment reform viewed as supportive for PMA technologies, yet shares fell 5.88%. On Nov 6, 2025, record Q3 2025 revenue and raised FY2025 guidance coincided with a 2.02% decline. Later, a successful FDA meeting and subsequent rolling BLA for ReNu in December 2025 brought modest gains of 0.21% and 2.09%. A January 2026 promotion-focused article for an investment partner saw shares down 4.85%. Today’s earnings-date announcement fits into this backdrop of meaningful catalysts but uneven price responses.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th.
Management will host a conference call at 5:00 p.m. Eastern Time on February 26th to discuss the results of the quarter and the fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries:
ICR Healthcare
Mike Piccinino, CFA
OrganoIR@icrinc.com
Press and Media Inquiries:
Organogenesis
communications@organo.com
